ArticleGels (Basel, Switzerland)2025
Advanced PMSSO Hydrogel Cross-Linked Cyclodextrin Composite Carrier for Enhanced Oral Delivery of Iron to Treat Anemia.
Article in Gels (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Iron deficiency anemia continues to pose a significant global health burden, necessitating the development of improved therapeutic delivery systems. This study investigates novel composite materials composed of organosilicon hydrogels and cross-linked sulfobutyl ether beta-cyclodextrin (SBECD) nanoparticles for the oral delivery of iron compounds. Two types of cross-linked SBECD nanoparticles were synthesized using 1,6-hexamethylene diisocyanate. These nanoparticles were characterized by DLS, NTA, and FTIR and possess size around 200-300 nm and negative zeta-potential around -35 mV with molecular weight 150-200 kDa. Various hydrogel matrices, including plain PMSSO hydrogels and modified versions with amino groups or silicate cross-links, are also described. The hydrogels were evaluated for their iron sorption capacity (up to 44% loading efficiency) and release kinetics for 3 h. The results demonstrate that cross-linked SBECD nanoparticles significantly enhance iron sorption and provide sustained release under simulated physiological conditions. Mathematical modeling indicated that the Higuchi model best describes the iron release kinetics. The findings suggest that the proposed composite materials hold considerable promise for the treatment of iron deficiency anemia, offering an innovative approach to enhance therapeutic efficacy and minimize adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.